Assembly Biosciences (ASMB) vs Ovid Therapeutics (OVID)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Ovid Therapeutics (OVID) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 48.1% versus a loss of 10.5%. Over five years, OVID leads with a -35.0% price change compared with -41.7% for ASMB. Assembly Biosciences is the larger company by market cap ($464.6 million vs $457.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ASMB | OVID |
|---|---|---|
| Share price | $22.82 | $2.34 |
| Market cap | $464.63M | $457.00M |
| 1-day change | -0.57% | -0.85% |
| YTD return | -32.90% | +43.56% |
| 1-year return | -10.51% | +48.10% |
| 5-year return | -41.67% | -35.00% |
| P/E ratio (TTM) | 21.94 | — |
| EPS (TTM) | $1.04 | $-0.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $39.71 | $3.11 |
| 52-week low | $21.80 | $1.18 |
| Distance from 52-week high | -42.53% | -24.64% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +127.87% | +157.26% |
| Average volume | 279.78K | 1.57M |
| Shares outstanding | 20.36M | 195.30M |
| Employees | 73 | 23 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OVID has outperformed ASMB by 58.6 percentage points over the past year.
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
About Ovid Therapeutics
OVID stock →Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
ASMB vs OVID FAQ
Which is bigger, Assembly Biosciences or Ovid Therapeutics?
Assembly Biosciences (ASMB) is larger, with a market capitalization of $464.63M compared with $457.00M for Ovid Therapeutics (OVID).
Which stock has performed better over the past year, ASMB or OVID?
OVID returned +48.10% over the past 12 months, compared with -10.51% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Assembly Biosciences and Ovid Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.